Abbvie Inc banner

Abbvie Inc
F:4AB

Watchlist Manager
Abbvie Inc Logo
Abbvie Inc
F:4AB
Watchlist
Price: 191.5 EUR 0.39% Market Closed
Market Cap: €338.2B

Wall St Price Targets

4AB Price Targets Summary
Abbvie Inc

Wall Street analysts forecast 4AB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 4AB is 226.04 EUR with a low forecast of 166.48 EUR and a high forecast of 302.14 EUR.

Lowest Forecast
Price Target
166.48 EUR
13% Downside
Average Forecast
Price Target
226.04 EUR
18% Upside
Highest Forecast
Price Target
302.14 EUR
58% Upside
Abbvie Inc Competitors:
Price Targets
USEG
US Energy Corp
174% Upside
QXO
SilverSun Technologies Inc
79% Upside
ZEAL
Zealand Pharma A/S
99% Upside
QTTB
Homology Medicines Inc
22% Upside
FBIZ
First Business Financial Services Inc
11% Upside

Revenue
Forecast

9% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss
9% / Year
Past Growth
9% / Year
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 3 years is 9%.

Gross Profit
Forecast

9% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-17%
Average Miss
9% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-17%
Average Miss

Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 3 years is 15%.

Operating Income
Forecast

12% / Year
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss
12% / Year
Past Growth
25% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss

Over the last 14 years, the compound annual growth rate for Operating Income has been 12%. The projected CAGR for the next 3 years is 25%.

Pre-Tax Income
Forecast

4% / Year
Past Growth
81% / Year
Estimated Growth
Estimates Accuracy
-51%
Average Miss
4% / Year
Past Growth
81% / Year
Estimated Growth
Estimates Accuracy
-51%
Average Miss

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 4%. The projected CAGR for the next 3 years is 81%.

Net Income
Forecast

1% / Year
Past Growth
98% / Year
Estimated Growth
Estimates Accuracy
-52%
Average Miss
1% / Year
Past Growth
98% / Year
Estimated Growth
Estimates Accuracy
-52%
Average Miss

Over the last 14 years, the compound annual growth rate for Net Income has been 1%. The projected CAGR for the next 3 years is 98%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 4AB's stock price target?
Price Target
226.04 EUR

According to Wall Street analysts, the average 1-year price target for 4AB is 226.04 EUR with a low forecast of 166.48 EUR and a high forecast of 302.14 EUR.

What is the Revenue forecast for Abbvie Inc?
Projected CAGR
9%

Over the last 14 years, the compound annual growth rate for Revenue has been 9%. The projected CAGR for the next 3 years is 9%.

What is the Gross Profit forecast for Abbvie Inc?
Projected CAGR
15%

Over the last 14 years, the compound annual growth rate for Gross Profit has been 9%. The projected CAGR for the next 3 years is 15%.

What is the Operating Income forecast for Abbvie Inc?
Projected CAGR
25%

Over the last 14 years, the compound annual growth rate for Operating Income has been 12%. The projected CAGR for the next 3 years is 25%.

What is the Pre-Tax Income forecast for Abbvie Inc?
Projected CAGR
81%

Over the last 14 years, the compound annual growth rate for Pre-Tax Income has been 4%. The projected CAGR for the next 3 years is 81%.

What is the Net Income forecast for Abbvie Inc?
Projected CAGR
98%

Over the last 14 years, the compound annual growth rate for Net Income has been 1%. The projected CAGR for the next 3 years is 98%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett